Description
Retatrutide + Tirzepatide Blend research blend
Retatrutide + Tirzepatide Blend combines retatrutide, an investigational GIP/GLP-1/glucagon triple agonist, with tirzepatide, a GIP/GLP-1 dual agonist, for comparative incretin research.
Product details
| Compound | Retatrutide and Tirzepatide |
|---|---|
| Class | Incretin receptor agonist blend |
| Form | Peptides |
| Size | 60mg |
| Labelling | Compound name and strength on every container |
Select your format and strength from the options above.
What Retatrutide + Tirzepatide Blend research has examined
- Retatrutide: triple receptor agonism.
- Tirzepatide: dual GIP/GLP-1 agonism.
- Comparative research: overlapping and distinct receptor profiles.
Research interest does not establish a proven effect in humans.
Regulatory status
Tirzepatide is the active ingredient of prescription-only licensed medicines, and retatrutide is investigational. This blend is a research chemical, not a licensed medicine, and is not approved for any use in humans.
Storage and handling
Store lyophilised vials cold, dry and away from light. Reconstitute with a suitable sterile diluent under aseptic conditions and keep solutions refrigerated. See our peptide reconstitution guide.
Related research products
Retatrutide + Cagrilintide · Tirzepatide + Semaglutide Blend · Retatrutide · All peptides
References
For laboratory research use only. Not for human or animal consumption. Not intended to diagnose, treat, cure or prevent any disease.
Reviews
There are no reviews yet.